Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345019 · ClinicalTrials.gov registry record · Phase 3
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,718
- Enrollment target
NCT01345019 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 1,718 participants.
The verdict
NCT01345019, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,718 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
Interventions
- DRUG Zoledronic acid
- DRUG Denosumab
- DRUG Placebo to Denosumab
- DRUG Placebo to zoledronic acid
- DRUG Denosumab (for the open-label treatment phase)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,718 participants |
| Start Date | 2012-05-17 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345019
The ClinicalTrials.gov registry entry for NCT01345019 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,718 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Zoledronic acid is the first listed.
NCT01345019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01345019 about?
NCT01345019 is a clinical study titled "Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma". The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
What is the current status of trial NCT01345019?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,718 participants. The study started on 2012-05-17. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT01345019?
The interventions under investigation include: Zoledronic acid (DRUG), Denosumab (DRUG), Placebo to Denosumab (DRUG), Placebo to zoledronic acid (DRUG), Denosumab (for the open-label treatment phase) (DRUG).
Who is sponsoring clinical trial NCT01345019?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.